Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter Baumannii

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2286-2298

  Yadav, Rajbharan ^a   Landersdorfer, Cornelia B ^a,b   Nation, Roger L ^a   Boyce, John D ^c   Bulitta, Jürgen B ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY AT BUFFALO   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; BETA LACTAM; BIAPENEM; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFEPIME; CEFSULODIN; CEFTAZIDIME; DORIPENEM; IMIPENEM; ISEPAMICIN; MEROPENEM; SULBACTAM; TOBRAMYCIN; ANTIINFECTIVE AGENT; DRUG COMBINATION;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; COLONY FORMING UNIT; CONCENTRATION AT STEADY-STATE; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL; ACINETOBACTER INFECTIONS; BACTERIAL COUNT; COMPUTER SIMULATION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MONTE CARLO METHOD;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLONY COUNT, MICROBIAL; COMPUTER SIMULATION; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD;

EID: 84928891833     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04379-14     Document Type: Article

References (56)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
2. Infectious Diseases Society of AmericaSpellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert DN. 2011. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 52(Suppl 5):S397-S428. http://dx.doi.org/10.1093/cid/cir153.
3. Walker B, Barrett S, Polasky S, Galaz V, Folke C, Engstrom G, Ackerman F, Arrow K, Carpenter S, Chopra K, Daily G, Ehrlich P, Hughes T, Kautsky N, Levin S, Maler KG, Shogren J, Vincent J, Xepapadeas T, de Zeeuw A. 2009. Looming global-scale failures and missing institutions. Science 325:1345-1346. http://dx.doi.org/10.1126/science.1175325.
4. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323-2329. http://dx.doi.org/10.1001/jama.2009.1754.
5. Chastre J, Trouillet JL. 2000. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Semin Respir Infect 15:287-298. http://dx.doi.org/10.1053/srin.2000.20944.
6. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gibert C. 1989. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 139:877-884.
7. Mak JK, Kim MJ, Pham J, Tapsall J, White PA. 2009. Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 63:47-54. http://dx.doi.org/10.1093/jac/dkn454. Yadav et al.
8. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:3471-3484. http://dx.doi.org/10.1128/AAC.01464-06.
9. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
10. Ho J, Tambyah PA, Paterson DL. 2010. Multiresistant Gram-negative infections: a global perspective. Curr Opin Infect Dis 23:546-553. http://dx.doi.org/10.1097/QCO.0b013e32833f0d3e.
11. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. 2010. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 16:209-215. http://dx.doi.org/10.1089/mdr.2010.0052.
12. Lim TP, Ledesma KR, Chang KT, Hou JG, Kwa AL, Nikolaou M, Quinn JP, Prince RA, Tam VH. 2008. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 52:2898-2904. http://dx.doi.org/10.1128/AAC.01309-07.
13. Milatovic D, Braveny I. 1987. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 6:234-244. http://dx.doi.org/10.1007/BF02017607.
14. Peleg AY, Franklin C, Bell JM, Spelman DW. 2006. Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia. Infect Control Hosp Epidemiol 27:759-761. http://dx.doi.org/10.1086/507012.
15. Joly-Guillou ML, Decre D, Herrman JL, Bourdelier E, Bergogne-Berezin E. 1995. Bactericidal in-vitro activity of beta-lactams and betalactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. J Antimicrob Chemother 36:619-629. http://dx.doi.org/10.1093/jac/36.4 .619.
16. Owens RC, Jr, Banevicius MA, Nicolau DP, Nightingale CH, Quintiliani R. 1997. In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates. Antimicrob Agents Chemother 41:2586-2588.
17. Tod M, Padoin C, Petitjean O. 2000. Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clin Pharmacokinet 38:205-223. http://dx.doi.org/10.2165/00003088-200038030-00002.
18. Coyne S, Courvalin P, Perichon B. 2011. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother 55:947-953. http://dx.doi.org/10.1128/AAC.01388-10.
19. Bulitta JB, Landersdorfer CB, Forrest A, Brown SV, Neely MN, Tsuji BT, Louie A. 2011. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol 12:2044-2061. http://dx.doi.org/10.2174/138920111798808428.
20. Landersdorfer CB, Ly NS, Xu H, Tsuji BT, Bulitta JB. 2013. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother 57:2343-2351. http://dx.doi.org/10.1128/AAC .00092-13.
21. Obara M, Nakae T. 1991. Mechanisms of resistance to beta-lactam antibiotics in Acinetobacter calcoaceticus. J Antimicrob Chemother 28:791-800. http://dx.doi.org/10.1093/jac/28.6.791.
22. Sato K, Nakae T. 1991. Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance. J Antimicrob Chemother 28:35-45. http://dx.doi.org/10.1093/jac/28.1.35.
23. Bulitta JB, Shan J, Velkov T, Landersdorfer CB. 2013. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, Abstract: A-2459.
24. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing: 25th informational supplement. M100-S125. CLSI, Wayne, PA.
25. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters, version 5.0. http://www.eucast.org/clinical-breakpoints/.
26. Conil JM, Georges B, Ruiz S, Rival T, Seguin T, Cougot P, Fourcade O, Houin G, Saivin S. 2011. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 71:61-71. http://dx.doi.org/10.1111/j.1365-2125.2010.03793.x.
27. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sorgel F. 2007. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenemcilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 51:3304-3310. http://dx.doi.org/10.1128/AAC.01318-06.
28. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D'Hondt RE, Jusko WJ, Forrest A, Tsuji BT. 2010. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 54:2051-2062. http://dx.doi.org/10.1128/AAC.00881-09.
29. Nicasio AM, Bulitta JB, Lodise TP, D'Hondt RE, Kulawy R, Louie A, Drusano GL. 2012. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model. Antimicrob Agents Chemother 56:682-686. http://dx.doi.org/10.1128/AAC.05664-11.
30. Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL. 2010. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother 54:2638-2645. http://dx.doi.org/10.1128/AAC.01721-09.
31. Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT. 2009. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:46-56. http://dx.doi.org/10.1128/AAC.00489-08.
32. Maidhof H, Johannsen L, Labischinski H, Giesbrecht P. 1989. Onset of penicillin-induced bacteriolysis in staphylococci is cell cycle dependent. J Bacteriol 171:2252-2257.
33. Kadurugamuwa JL, Clarke AJ, Beveridge TJ. 1993. Surface action of gentamicin on Pseudomonas aeruginosa. J Bacteriol 175:5798-5805.
34. Kadurugamuwa JL, Lam JS, Beveridge TJ. 1993. Interaction of gentamicin with the A band and B band lipopolysaccharides of Pseudomonas aeruginosa and its possible lethal effect. Antimicrob Agents Chemother 37:715-721. http://dx.doi.org/10.1128/AAC.37.4.715.
35. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre-and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 13:201-211. http://dx.doi.org/10.1208/s12248-011-9257-x.
36. Bulitta JB, Landersdorfer CB. 2011. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J 13:212-226. http://dx.doi.org/10.1208/s12248-011-9258-9.
37. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 51:2497-2507. http://dx.doi.org/10.1128/AAC.01477-06.
38. Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandez PB, Ambrose PG. 2011. Application of pharmacokineticpharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis 52(Suppl 7):S513-519. http://dx.doi.org/10.1093/cid/cir166
39. Gould IM, Milne K. 1997. In-vitro pharmacodynamic studies of piperacillin/ tazobactam with gentamicin and ciprofloxacin. J Antimicrob Chemother 39:53-61. http://dx.doi.org/10.1093/jac/39.1.53.
40. Marques MB, Brookings ES, Moser SA, Sonke PB, Waites KB. 1997. Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 41:881-885.
41. Savov E, Chankova D, Vatcheva R, Dinev N. 2002. In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin. Int J Antimicrob Agents 20:390-392. http://dx.doi.org/10.1016/S0924-8579(02)00207-8.
42. Elkhaili H, Pompei D, Linger L, Kamili N, Monteil H, Jehl F. 1996. Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperprod uctive in cephalosporinase. Pathol Biol 44:367-373.
43. Glew RH, Moellering RC, Jr, Buettner KR. 1977. In vitro synergism between carbenicillin and aminoglycosidic aminocyclitols against Acinetobacter calcoaceticus var. anitratus. Antimicrob Agents Chemother 11: 1036-1041. http://dx.doi.org/10.1128/AAC.11.6.1036.
44. Principe L, Capone A, Mazzarelli A, D'Arezzo S, Bordi E, Di Caro A, Petrosillo N. 2013. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Microb Drug Resist 19:407-414. http://dx.doi.org/10.1089/mdr.2012.0250.
45. Roussel-Delvallez M, Wallet F, Delpierre F, Courcol RJ. 1996. In vitro bactericidal effect of a beta-lactam+aminoglycoside combination against multiresistant Pseudomonas aeruginosa and Acinetobacter baumannii. J Chemother 8:365-368. http://dx.doi.org/10.1179/joc.1996.8.5.365.
46. Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VH. 2010. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis 201:889-897. http://dx.doi.org/10.1086/651024.
47. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F. 2004. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54:1085-1091. http://dx.doi.org/10.1093/jac/dkh485.
48. Andes D, Craig WA. 2002. Animal model pharmacokinetics and harmacodynamics: a critical review. Int J Antimicrob Agents 19:261-268. http://dx.doi.org/10.1016/S0924-8579(02)00022-5.
49. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86. http://dx.doi.org/10.1086/510079.
50. Drusano GL, Liu W, Fikes S, Cirz R, Robbins N, Kurhanewicz S, Rodriquez J, Brown D, Baluya D, Louie A. 2014. Interaction of drugand granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. J Infect Dis 210:1319-1324. http://dx.doi.org/10.1093/infdis/jiu237.
51. Drusano GL, Liu W, Kulawy R, Louie A. 2011. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 55:5300-5305. http://dx.doi.org/10.1128/AAC.00502-11.
52. Okusanya OO, Tsuji BT, Bulitta JB, Forrest A, Bulik CC, Bhavnani SM, Fernandes P, Ambrose PG. 2011. Evaluation of the pharmacokineticspharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagn Microbiol Infect Dis 70:101-111. http://dx.doi.org/10.1016/j.diagmicrobio.2011.03.001.
53. Matar KM, Al-lanqawi Y, Abdul-Malek K, Jelliffe R. 2013. Amikacin population pharmacokinetics in critically ill Kuwaiti patients. Biomed Res Int 2013:202818. http://dx.doi.org/10.1155/2013/202818.
54. Roberts JA, Lipman J. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851. http://dx.doi.org/10.1097/CCM.0b013e3181961bff.
55. Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. 2014. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 69:2043-2055. http://dx.doi.org/10.1093/jac/dku111.
56. Koppel BS, Hauser WA, Politis C, van Duin D, Daras M. 2001. Seizures in the critically ill: the role of imipenem. Epilepsia 42:1590-1593. http://dx.doi.org/10.1046/j.1528-1157.2001.34701.x.